Catalyzes a carbon-carbon cleavage reaction; cleaves a 2-hydroxy-3-methylacyl-CoA into formyl-CoA and a 2-methyl-branched fatty aldehyde.
|CAT||Product Name||Target Species||Antibody Clone||Antibody Host||Epitope||HLA||Vector Type|
|TCR-C002Z||Human anti-HACL1 T cell receptor (121), pCDTCR1||Human||121||Human||QFADVIVLF||HLA-B*3501||Lentiviral|
|CAT||Product Name||Clone||Promotor||Packaging System||Targeting Diseases|
|VP-TCR-C180||Lenti-HACL1 T cell receptor (121) Viral Particle||121||CMV||Lentivirus|
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE